Cerity Partners LLC Purchases 11,247 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Cerity Partners LLC boosted its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 21.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 62,796 shares of the medical device company’s stock after purchasing an additional 11,247 shares during the period. Cerity Partners LLC owned about 0.10% of Tandem Diabetes Care worth $2,663,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its holdings in shares of Tandem Diabetes Care by 5.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 38,732 shares of the medical device company’s stock worth $1,372,000 after acquiring an additional 1,985 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Tandem Diabetes Care by 11.2% during the second quarter. GAMMA Investing LLC now owns 4,276 shares of the medical device company’s stock worth $172,000 after purchasing an additional 431 shares during the last quarter. LVW Advisors LLC increased its stake in shares of Tandem Diabetes Care by 15.1% in the second quarter. LVW Advisors LLC now owns 7,869 shares of the medical device company’s stock valued at $317,000 after buying an additional 1,034 shares in the last quarter. Diversified Trust Co raised its holdings in shares of Tandem Diabetes Care by 11.1% in the second quarter. Diversified Trust Co now owns 14,635 shares of the medical device company’s stock valued at $590,000 after buying an additional 1,462 shares during the last quarter. Finally, ORG Partners LLC acquired a new position in Tandem Diabetes Care during the 2nd quarter worth about $31,000.

Insider Buying and Selling at Tandem Diabetes Care

In related news, Director Kim D. Blickenstaff sold 10,000 shares of the firm’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $30.00, for a total transaction of $300,000.00. Following the sale, the director now directly owns 195,190 shares in the company, valued at $5,855,700. This trade represents a 4.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 2.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Robert W. Baird dropped their target price on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating for the company in a research note on Thursday, November 7th. Canaccord Genuity Group reduced their price objective on Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. The Goldman Sachs Group assumed coverage on Tandem Diabetes Care in a research note on Friday, October 4th. They issued a “neutral” rating and a $46.00 target price for the company. Barclays upped their price target on Tandem Diabetes Care from $58.00 to $60.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. Finally, Royal Bank of Canada started coverage on Tandem Diabetes Care in a research report on Wednesday, October 2nd. They issued an “outperform” rating and a $65.00 price objective for the company. Five investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Tandem Diabetes Care currently has an average rating of “Moderate Buy” and an average target price of $54.25.

Tandem Diabetes Care Price Performance

TNDM opened at $30.63 on Friday. The stock has a market cap of $2.01 billion, a P/E ratio of -15.87 and a beta of 1.36. Tandem Diabetes Care, Inc. has a 12 month low of $18.45 and a 12 month high of $53.69. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. The company has a fifty day simple moving average of $34.88 and a 200 day simple moving average of $40.79.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings results on Wednesday, November 6th. The medical device company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.08. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The company had revenue of $243.97 million for the quarter, compared to analyst estimates of $224.14 million. During the same quarter last year, the firm posted ($0.38) earnings per share. Tandem Diabetes Care’s revenue was up 31.4% compared to the same quarter last year. On average, research analysts expect that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.